Solid lipid nanoparticles:: Formulation factors affecting cell transfection capacity

被引:91
作者
del Pozo-Rodriguez, A. [1 ]
Delgado, D. [1 ]
Solinis, M. A. [1 ]
Gascon, A. R. [1 ]
Pedraz, J. L. [1 ]
机构
[1] Univ Basque Country UPV EHU, Fac Pharm, Pharm & Pharmaceut Technol Lab, Vitoria 01006, Spain
关键词
solid lipid nanoparticles; non-viral vectors; gene therapy; in vitro" transfection;
D O I
10.1016/j.ijpharm.2007.03.015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Since solid lipid nanoparticles (SLNs) were introduced as non-viral transfection systems, very few reports of their use for gene delivery have been published. In this work different formulations based on SLN-DNA complexes were formulated in order to evaluate the influence of the formulation components on the "in vitro" transfection capacity. SLNs composed by the solid lipid Precirol(R) ATO 5, the cationic lipid DOTAP and the surfactant Tween 80, and SLN-DNA complexes prepared at different DOTAP/DNA ratios were characterized by studying their size, surface charge, DNA protection capacity, transfection and cell viability in HEK293 cultured cells. The incorporation of Tween 80 allowed for the reduction of the cationic lipid concentration. The formulations prepared at DOTAP/DNA ratios 7/1, 5/1 and 4/1 provided almost the same transfection levels (around 15% transfected cells), without significant differences between them (p > 0.05). Other assayed formulations presented lower transfection. Transfection activity was dependent on the DOTAP/DNA ratio since it influences the DNA condensation into the SLNs. DNA condensation is a crucial factor which conditions the transfection capacity of SLNs, because it influences DNA delivery from nanoparticles, gene protection from external agents and DNA topology. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:261 / 268
页数:8
相关论文
共 25 条
[1]   Formation and intracellular trafficking of lipoplexes and polyplexes [J].
Elouahabi, A ;
Ruysschaert, JM .
MOLECULAR THERAPY, 2005, 11 (03) :336-347
[2]  
Elouahabi A, 2003, METHOD ENZYMOL, V373, P313
[3]   Evaluation of lipid-based reagents to mediate intracellular gene delivery [J].
Faneca, H ;
Simoes, S ;
de Lima, MCP .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2002, 1567 (1-2) :23-33
[4]   Analytical methods for the characterization of cationic lipid nucleic acid complexes [J].
Ferrari, ME ;
Nguyen, CM ;
Zelphati, O ;
Tsai, YL ;
Felgner, PL .
HUMAN GENE THERAPY, 1998, 9 (03) :341-351
[5]   Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase [J].
Freitas, C ;
Müller, RH .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1999, 47 (02) :125-132
[6]   Development of biomaterials for gene therapy [J].
Han, S ;
Mahato, RI ;
Sung, YK ;
Kim, SW .
MOLECULAR THERAPY, 2000, 2 (04) :302-317
[7]  
Harvie P, 2000, J PHARM SCI, V89, P652, DOI 10.1002/(SICI)1520-6017(200005)89:5<652::AID-JPS11>3.0.CO
[8]  
2-H
[9]   HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes [J].
Hyndman, L ;
Lemoine, JL ;
Huang, L ;
Porteous, DJ ;
Boyd, AC ;
Nan, XS .
JOURNAL OF CONTROLLED RELEASE, 2004, 99 (03) :435-444
[10]   Effect of non-ionic surfactants on the formation of DNA/emulsion complexes and emulsion-mediated gene transfer [J].
Liu, F ;
Yang, JP ;
Huang, L ;
Liu, DX .
PHARMACEUTICAL RESEARCH, 1996, 13 (11) :1642-1646